(Q56771952)

1

0 references

Masahiro Mori

2

0 references

Kimihito Arai

3

0 references

Yasunori Sato

4

0 references

Sei Hayakawa

5

0 references

Saeko Masuda

6

0 references

Junko Taniguchi

Multiple Sclerosis Journal

7

0 references

publication date

25 August 2010

0 references

published in

0 references

volume

16

0 references

issue

12

0 references

page(s)

1443-1452

0 references

cites work

The clinical course of neuromyelitis optica (Devic's syndrome).

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

The spectrum of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

"Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Chemokines--chemotactic cytokines that mediate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

IL-17 family cytokines and the expanding diversity of effector T cell lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

The IL-23/IL-17 axis in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247

IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379247